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Abstract
Purpose: The aim of this study was to compare the postoperative clinical and radiological data of
patients with vestibular schwannomas who were initially managed by near total resection (NTR) or
subtotal resection (STR). The Ki-67 analysis results were compared with tumor regrowth to
determine the presence of a correlation between this proliferative index and postoperative tumor
regrowth.
Study Design: Seventeen adult patients (7 male, 10 female) were retrospectively reviewed. Nine
(52.9%) and eight (47.1%) patients underwent NTR and STR, respectively. Postoperative clinical
and radiological data associated with vestibular schwannoma growth were compared with the Ki-
67 immunohistochemical analysis results.
Results: Evidence of clinically significant regrowth was observed in four (23.5%) patients. Patients
who underwent NTR had a lower rate/incidence of tumor regrowth than did patients who
underwent STR. Patients with a higher Ki-67 index had the highest tumor regrowth rates.
Conclusions: Our study indicates that assessment of the Ki-67 index may be useful for
determining the probability of regrowth of vestibular schwannomas when only partial removal is
accomplished.
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Introduction
Vestibular schwannoma (VS) is the most
common tumor of the cerebellopontine
angle, and microsurgical removal remains
central to its management.1,2 The goals of
surgical removal are complete tumor eradi-
cation with preservation of the facial nerve
and thus cochlear function.1,2 However,
achieving complete tumor eradication with-
out compromising the function of important
structures such as the brain stem, vessels,
and other nerves in the cerebellopontine
angle is impossible in some patients because
of the tumor’s intimate relationship with
these structures.1–6
Increasing attention is being given to the
risk of postoperative facial palsy because of
the high importance of aesthetics to many
patients. This means that even minimal
facial paralysis may be poorly tolerated by
some patients.2,4–6
The surgeon faces the dilemma of
whether to preserve the nerve at the cost
of leaving a small remnant of tumor or to
achieve total eradication at the cost of
increasing the risk of facial injury.1,2,7
Historically, complete tumor resection was
often prioritized at the expense of normal
facial nerve function. At present, however,
the decision regarding whether to perform
total surgical removal may be a source of
debate for patients during the consultation
phase.
Reviews of the literature have revealed
that in the event of partial removal, the
residual VS in patients who had undergone
near total resection (NTR) versus subtotal
resection (STR) showed an incidence of
regrowth ranging from 0.0% to 3.5%
versus 18.4% to 73.9%, respectively.1,8–15
The ability to monitor the residual tumor
with magnetic resonance imaging (MRI),
advances in revision microsurgery, and the
development of stereotactic radiosurgery
allow for adequate management when a
VS regrows after partial resection.1,10,15
The molecular mechanisms associated
with the formation of a VS secondary to
impaired growth regulation remain
unclear.16,17 Identification of these mechan-
isms could be of great clinical value for
planning the postoperative management of
patients who have undergone incomplete
tumor resection.18
Although numerous immunohistochem-
ical tests are able to provide information
that can be used to estimate tumor growth
rates and patterns, the Ki-67 index is still
one of the most widely used markers of cell
proliferation.17–20 Some researchers have
analyzed the Ki-67 proliferative index of
VS.16–24 Charabi et al.,21,22 who were the
first to describe the growth rate of VSs as
expressed by Ki-67 in relation to symptom
duration, reported that tumors with a high
proliferative status showed a short pre-
operative symptom duration, while tumors
with a low proliferative status had a long
symptom duration. Subsequently, other
authors assumed that tumor growth was
positively associated with a higher prolifera-
tive status as expressed by Ki-67.16–18,23,24
However, no studies have been performed to
analyze the correlation between partial VS
resection and the Ki-67 index.
We herein report the results obtained
from a review of patients with a sporadic
unilateral VS who were initially managed by
NTR or STR and subsequent periodic
follow-up with MRI. The aim of this paper
is to report the results of partial VS resec-
tion and compare the postoperative
clinical and radiological data with the
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immunohistochemical analysis of Ki-67 to
determine the presence of a correlation
between this proliferative index and post-
operative tumor regrowth.
Materials and methods
This retrospective study included 17 con-
secutive adult patients (7 male, 10 female)
surgically treated for a VS in the
Otorhinolaryngology Division of Sapienza
University of Rome from 2002 to 2012. The
patients selected for this study underwent
partial resection of the tumor by a transla-
byrinthine approach or retrosigmoid
approach because of a high risk of intrao-
perative and postoperative complications.
Either NTR or STR was performed.
Ninety-eight patients who underwent
total VS resection (100% tumor clearance
according to the surgeon’s subjective obser-
vation and the 6-month postoperative MRI
findings) in our institute during the same
period of time were excluded from the study.
In the present study, NTR was defined as
>95% resection with an intracanalicular
tumor remnant or adherence of the tumor
to the facial nerve or brain stem. STR was
defined as <95% tumor resection. This
classification was adopted in accordance
with a recent study by El-Kashlan et al.15
The initial tumor size was defined as the
tumor diameter on preoperative gadoli-
nium-enhanced MRI.
The preoperative symptom duration,
postoperative complications, any subse-
quent treatment, and the degree of post-
operative facial paralysis were assessed. All
patients underwent postoperative MRI at
6 months and annually throughout the
observation period to evaluate any possible
growth of the residual tumor.
Long-term VS regrowth was assessed in
each patient by MRI performed 6 months
postoperatively and annually thereafter
until before the date of the study. The
duration of follow-up ranged from 2 to 12
years (median, 6.7 years). No patients
underwent postoperative radiosurgery.
Immunohistochemical staining for the
nuclear proliferation-associated antigen Ki-
67 was performed using the mouse mono-
clonal antibody MIB1. The Ki-67 index was
estimated as the percentage of stained cell
nuclei (marked antigen Ki-67) among all
nuclei visible in the field. Ki-67 analysis was
performed by the same researcher (C.D.G.)
for minimum variability and later confirmed
by a second scientist (R.C.) in a blinded
fashion. The specimens of patients who
underwent operations at the second hospital
were evaluated by the same pathologists. We
considered a Ki-67 index of >2.5% to
indicate high cell proliferation as reported
in similar studies.18–24
Outcomes were calculated starting from
the date of surgery. Growth of the residual
tumor was determined by an increase in its
maximum diameter on follow-up imaging
studies. Only tumor growth of >0.5 cm of
the estimated postoperative size was con-
sidered to indicate clinical tumor recurrence.
Postoperative clinical and radiological
data associated with VS growth were com-
pared with the Ki-67 immunohistochemical
analysis results, and the efficacy of this
proliferative tumor index in identifying
tumor growth in cases of partial resection
was estimated.
The statistical analysis was performed
using the chi-square test and regression
analysis.
The study was performed in accordance
with the Declaration of Helsinki and
received prior approval from our institu-
tional ethics committee.
Results
Preoperative, intraoperative,
and postoperative clinical data
The mean age of the patients at surgery was
58.1 years (range, 48–74 years). Seven
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tumors were located on the right side and 10
on the left side. The most common symptom
at the time of presentation was progressive
hearing loss, which was reported in all
patients of the study (100%). Other symp-
toms included tinnitus (58.8%), vertigo
(52.9%), and aural fullness (17.6%).
Preoperative facial paralysis (grade II) was
reported in two patients (11.7%) (Table 1).
Five (29.4%) patients underwent hearing
preservation surgery.
Nine (52.9%) and eight (47.1%) patients
underwent NTR and STR, respectively.
The preoperative tumor size ranged from
1.5 to 4.0 cm with an estimated mean of
2.3 cm.
Intraoperatively, tumor adherence to the
facial nerve was present in 14 (82.3%)
patients, to the brain stem in 6 (35.3%), and
to both of these nervous structures in 3
(17.6%). Complete resection of the tumor
without complications such as facial dissection
or serious life-threatening risks was considered
impossible in all patients (Table 1).
Three (17.6%) patients developed post-
operative grade II facial palsy according to
the House–Brackmann (HB) classification,
while only one (5.8%) patient developed
grade III palsy. The remaining 13 (76.4%)
patients developed grade I paralysis
(Table 1). No patients received
postoperative radiation therapy or other
surgical treatments.
Ki-67 index evaluation
The Ki-67 labeling index in our study varied
from 0.5% to 4.3% with a mean of 1.8%. In
five patients, the Ki-67 proliferation index
was >2.5% (Figure 1).
Ki-67 index and preoperative tumor size
No correlation was found between the Ki-67
index and preoperative tumor size in our
group of patients. Only one patient with a
VS size of 3 cm showed a relatively high Ki-
67 index of 2.8%, whereas another patient
with a low Ki-67 index of 0.8% had a VS of
4 cm. No significant correlation was found
between the Ki-67 index and patient age
or sex.
Postoperative regrowth
The postoperative tumor size was evaluated
at 6 months, 1 year, and shortly before the
date of the study (Figure 2). The median
long-term follow-up duration was 6.7 years
(range, 2–12 years).
Evidence of regrowth was observed in
four (23.5%) patients; the tumor size
Table 1. Preoperative, intraoperative, and postoperative clinical data.
Preoperative
symptoms Patients
Reason for
intraoperative
subtotal resection Patients
Postoperative
facial palsy
(grade) Patients
Facial palsy 2 (11.7) Tumor adherent to facial nerve 14 (82.3) I 13 (76.4)
Hearing loss 17 (100.0) Tumor adherent to brain stem 6 (35.3) II 3 (17.6)
Tinnitus 10 (58.8) Tumor adherent to brain stem
and facial nerve
3 (17.6) III 1 (5.8)
Vertigo 9 (52.9) IV–VI –
Aural fullness 3 (17.6)
Hydrocephalus 1 (5.8)
Data are presented as n (%).
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increased by 0.6 cm in three patients
and by 0.5 cm in one patient. In 12
(70.5%) patients, no evidence of regrowth
was evident (Table 2). A reduction of 0.5 cm
in the tumor size in was observed in one
patient (Patient 11).
Patients who underwent NTR had a
lower tumor regrowth rate than did patients
who underwent STR (5.8% vs. 17.6%,
respectively) (Table 2). However, the chi-
square test revealed no significant difference
between the two groups.
Figure 2. Postoperative tumor size at 6 months, 1 year, and end of follow-up.
Figure 1. Percentage of Ki-67 in the study group.
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Ki-67 index and postoperative tumor
regrowth
Finally, we evaluated the correlation
between the Ki-67 proliferation index with
the percentage of tumor regrowth observed
at the last follow-up. The regression analysis
results showed that patients with a higher
Ki-67 index had the highest tumor regrowth
rates (p¼ 0.0002) (Figure 3). The five
patients with tumor regrowth of >0.5 cm
showed an average Ki-67 index of 3.2%.
Discussion
The goal of microsurgical VS removal is
complete tumor eradication with
preservation of the facial nerve function
and eventual hearing preservation.1,2 Total
resection of VSs, especially larger tumors,
increases the risk of facial nerve injury with a
negative impact on patients’ quality of
life.1–7 Falcioni et al.3 analyzed a series of
1052 patients with anatomically preserved
facial nerves and total tumor removal. The
authors reported a postoperative HB grade
of I or II in 684 (65%) patients, a grade III
FP in 309 (29.4%) patients, and unsatisfac-
tory results (HB grade IV–VI) in the remain-
ing 59 (5.6%) patients.
In certain circumstances, if complete sur-
gical eradication of a VS is impossible, NTR
or STR is indicated.1,2,10–12 Most authors
suggest that the rationale for complete
removal may evolve toward NTR or STR
when the risk of facial nerve paralysis
becomes unacceptably high. If regrowth is
demonstrated, the patients should be moni-
tored by MRI for residual tumor growth
postoperatively and eventually treated with
revision microsurgery or radiation therapy if
regrowth is demonstrated.1,10–14,25,26
In the present study, NTR and STR were
defined in accordance with a recent study by
El-Kashlan et al.15 Because NTR was
Figure 3. Comparison between Ki-67 proliferation index and postoperative tumor regrowth; regression
plot.
Table 2. Tumor regrowth after NTR and STR.
Patients No regrowth
Regrowth
of 0.5 cm
NTR 9 (52.9) 8 (47.1) 1 (5.8)
STR 8 (47.1) 5 (29.4) 3 (17.6)
Total 17 12 (70.5) 4 (23.5)
Data are presented as n (%).
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defined as>95% resection, even a very small
tumor residue or a thin tumor capsule
(<0.2 cm) remaining on the facial nerve
or brain stem was considered as intraopera-
tive NTR.
Increasing attention is being given to
aesthetics in the present surgical era, and
postoperative facial paralysis seriously com-
promises patients’ quality of life. Thus,
during the preoperative consultation,
increasing numbers of patients are becoming
seriously concerned about the possibility
that this complication may occur.4–6 Lee
et al.27 noted that the social impact of facial
nerve disability in patients is not correlated
with the degree of facial nerve damage and
that this varies from one individual to
another. The authors showed how even
minimal facial paralysis may be poorly
tolerated by some patients.
Unfortunately, the available data regard-
ing tumor regrowth, facial palsy, and the
need for subsequent re-intervention after
incomplete VS resection is limited because
of the small number of published studies of
these topics.1,8–15 Chen et al.1 analyzed
facial nerve outcomes after incomplete exci-
sion of VSs and reported a significant benefit
of this type of surgery in terms of post-
operative facial nerve function. Among 105
patients with normal preoperative facial
nerve function, the postoperative facial
nerve function was HB grade I and II in 51
patients (48.57%), HB grade III in 34
patients (32.38%), and HB grade IV to VI
in 20 patients (19.05%). Intraoperative
adherence between the VS and the facial
nerve was found in 82.3% of the patients in
the present study, and partial resection of
the tumor was performed in all of these
patients to preserve the nerve. Three patients
developed postoperative grade II facial par-
alysis, and only one developed postoperative
grade III facial paralysis. The remaining 13
patients developed postoperative grade I
facial paralysis. No differences in facial
nerve outcomes were observed between
patients who underwent NTR and those
who underwent STR.
The possibility of worsening facial par-
alysis after adjuvant radiotherapy should be
considered. Virk et al.14 performed a series
of 16 STRs and demonstrated that two
patients with an initial HB grade of I/II
facial paralysis developed grade V/VI palsy
following adjuvant radiation treatment.
Despite the satisfactory outcomes in
terms of postoperative complications and
minimal facial paralysis obtained after par-
tial VS removal, the possibility of tumor
regrowth should be considered and
evaluated.1,2,11,28–31
Several studies including only patients who
underwent either STR or NTR have indicated
that most incomplete VS resections are not
associated with a significant increase in the
recurrence rate.1,8–15 Chen et al.1 reported that
the incidence of VS regrowth in their NTR
subset ranged from 0.0% to 3.5%, while that
in their STR ranged from 18.4% to 73.9%.
Bloch et al.8 classified 52 patients who had
undergone incomplete VS resection into either
NTR or STR. Recurrence was observed in 1
(3%) of the 33 patients who underwent NTR
versus 6 (32%) of the 19 patients who under-
went STR.
Evidence of clinically significant
regrowth was observed in 23.5% of the
patients in the present study. In accordance
with published results, patients who under-
went NTR had a lower tumor regrowth rate
(5.8%) than did patients who underwent
STR (17.6%).1,8–15
In contrast to previous studies,1,8–10,13
despite an evident increase in tumor
regrowth in patients who underwent STR,
no significant differences were found
between the two groups. This finding was
probably influenced by the limited sample of
patients in our study.
The current management strategy
after NTR or STR includes monitoring
of the residual tumor with MRI and,
when VS regrowth occurs, performing
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microsurgical revision or stereotactic
radiosurgery.1,2,10–12,32–34
In published studies involving only par-
tial VS removal (analyzed in Table 3), VS
regrowth occurred in 189 (10.04%) cases.
Among these patients, 58 (30.6%) under-
went revision microsurgery, 111 (58.7%)
underwent stereotactic radiosurgery, and
20 (10.5%) were only observed.
In the management of large VS, the initial
combination of subtotal resection and
Gamma Knife surgery should also be
considered. This strategy might be reason-
able for decreasing the risk of both nerve
damage and growth of the residual VS.
However, only a few authors have evaluated
the results of this treatment
combination.35,36
Assessment of the cellular growth rate
may help to determine an adequate strategy
for managing patients undergoing partial
removal of VS. Several authors have
observed a relationship between tumor
growth and a higher proliferative status
expressed through Ki-67.16–18,21,22,24 Ki-67
is a proliferative marker that may be
expressed in numerous neoplastic condi-
tions, and antibodies to the Ki-67 protein
have been increasingly used as diagnostic
tools in different types of neoplasms.
Some researchers have analyzed the pro-
liferative Ki-67 index of VS.16–24 Bedavanija
et al.16 showed that large VSs exhibit
enhanced proliferative activity and higher
growth rates than do smaller tumors and
defined a tumor size of 18mm as highly
significant. Charabi et al.21,22 found a sig-
nificant inverse correlation between the dur-
ation of symptoms and proliferation index
in two series of 21 and 124 VSs but no
correlation between tumor size and
proliferation.
Yokoyama et al.23 evaluated the correl-
ation between various clinical parameters
and the Ki-67 staining index in 58 cases of
VS. The index ranged from 0.37% to 6.61%
(mean, 1.70%) and was not correlated with
age, sex, or initial tumor volume. Niemczyk
et al.24 subsequently used immunohisto-
chemical tests to demonstrate significant
differences in the Ki-67 index between
radiologically stable neuromas and evolving
tumors.
Our study confirmed the absence of a
correlation between the Ki-67 index and
preoperative tumor size. Moreover, no sig-
nificant correlation was found between the
Ki-67 index and the age or sex of the
patients. This finding does not mean that
the Ki-67 index is not a good marker of cell
proliferation in patients with VS; rather, it
confirms the unpredictable growth of neur-
omas, which may sometimes evolve very
slowly to a large size in the absence of
clinical symptoms that allow for establish-
ment of a diagnosis.
However, evaluating the proliferation
activity of VS could have practical signifi-
cance when there are doubts about the
effectiveness of partial removal of a VS.24
Understanding the pattern of residual tumor
regrowth would allow the surgeon to more
easily make decisions regarding the best type
of postoperative management.
In an attempt to evaluate the effectiveness
of partial resection in terms of a lower risk of
facial paralysis, the postoperative radio-
logical data regarding tumor regrowth in
our study were compared with the results of
immunohistochemical analysis of Ki-67.
The aim of this comparison was to correlate
the tumor index of proliferative activity
with the incidence/rate of postoperative
tumor regrowth following STR after an
average long-term follow-up observation
period of 6.7 years. The results of the
regression analysis showed that patients
with a higher Ki-67 index had the highest
rates of tumor regrowth.
In our opinion, Ki-67 should be used as a
marker of cell proliferation of VSs, and
when this index is high after partial resec-
tion, follow-up must be constant and
protracted.
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Unfortunately, the disadvantage of
immunohistochemical tests is that they can
only be conducted after surgery. The ability
to evaluate the Ki-67 index intraoperatively
could provide further useful information to
orient the surgeon toward partial resection
when the risk of postsurgical facial paralysis
is high. Further studies are underway to
evaluate this possibility. Obviously, a sig-
nificant correlation between the intraopera-
tive Ki-67 index and tumor regrowth would
have an impact on the management of VS.
Postoperative Ki-67 evaluation is rou-
tinely performed in our clinical practice for
patients undergoing partial VS resection
because it is a low-cost immunohistochemical
analysis that provides useful information
regarding regrowth. Based on our findings,
if NTR or STR is performed and the Ki-67
index is >2.5%, we recommend careful
radiological follow-up because of the greater
statistical probability that these patients have
tumor regrowth. If regrowth occurs, we
believe that a new surgical treatment or
radiation therapy should be discussed
between the patient and surgeon because of
the increased risk of facial nerve injury.
Conclusion
During the consultation phase, another sur-
gical option should be offered to the patient
as an alternative to total tumor removal to
reduce the risk of minor and major post-
operative complications.
Our study has shown that assessment of
the cellular growth rate using the Ki-67
index may help to determine the probability
of VS regrowth when only partial removal is
accomplished. Larger series would provide
definitive conclusions on this issue.
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